Michael D.

Michael D. has over 15 years of work experience in the biotechnology and pharmaceutical industries. In 2021, they began working as the Associate Director of Assay Development at Nucleix Ltd., a company that develops non-invasive cancer molecular diagnostic tests. From 2018 to 2021, they worked as a Senior Scientist and Manager at 10X Genomics, a company that enables single-cell NGS. From 2015 to 2018, they were a Senior Scientist and Manager at Asuragen Inc., a molecular diagnostics subsidiary. From 2012 to 2015, they were a Post-Doctoral Researcher in Medical Oncology at the Dana-Farber Cancer Institute, where they conducted translational oncology research. From 2006 to 2012, they were a Research Associate in Preclinical Drug Development at the UT Southwestern Medical Center, where they discovered the first small molecules capable of targeting Porcupine. From 2004 to 2006, they worked as a Chemical Formulator and GMP & IP Reviewer at Pace Analytical at 3M.

Michael D. began their educational journey by obtaining a Bachelor of Science (B.S.) in Biochemistry from the University of Wisconsin-Madison in 2004. Michael then went on to pursue a Doctor of Philosophy (Ph.D.) in Cell Regulation from UT Southwestern Medical Center, which they completed in 2011. Afterward, Michael D. became a Research Fellow in Medicine in Oncology at Harvard Medical School, which they completed in 2015. Michael also obtained a Project Management Professional (PMP) certification from the Project Management Institute in October 2017.